Considering this overexpression, CD38 emerged as an attractive immunotherapeutic target for MM a decade ago [2], daratumumab being the first anti-CD38 monoclonal antibody (mAb) approved for MM patients in 2015 [3]. Here, CD38 is linked to Miyoshi myopathy.